Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Takeda
ClinicalTrials.gov Identifier:
NCT01456130
First received: October 13, 2011
Last updated: March 17, 2014
Last verified: March 2014

October 13, 2011
March 17, 2014
November 2011
March 2013   (final data collection date for primary outcome measure)
Number of Participants With Treatment Emergent Adverse Events (TEAEs) [ Time Frame: 52 Weeks ] [ Designated as safety issue: Yes ]
An TEAE is any untoward medical occurrence in a clinical investigation participant administered a drug; it does not necessarily have a causal relationship with this treatment. A serious TEAE is defined as any untoward medical occurrence that resulted in death, was life threatening, required or prolonged inpatient hospitalization, resulted in persistent or significant disability or incapacity, led to a congenital anomaly/birth defect or was an important medical event that may have required intervention to prevent any of items above.
Number of Participants with Adverse Events [ Time Frame: 52 Weeks ]
Complete list of historical versions of study NCT01456130 on ClinicalTrials.gov Archive Site
  • Change From Baseline in Glycosylated Hemoglobin (HbA1c) [ Time Frame: Baseline and Week 52 ] [ Designated as safety issue: No ]
    The change in the value of glycosylated hemoglobin collected at Week 52 or at the final visit relative to Baseline.
  • Percentage of Participants With a Clinical Response [ Time Frame: Week 52 ] [ Designated as safety issue: No ]
    Clinical response is defined as an HbA1c level less than 5.8% or less than 6.5% at Week 52 or at the final visit.
  • Change From Baseline in Fasting Glucose [ Time Frame: Baseline and Week 52 ] [ Designated as safety issue: No ]
    The change in the value of fasting glucose collected at Week 52 or the final visit relative to Baseline.
Not Provided
Not Provided
Not Provided
 
Long-term Study of Alogliptin as an Add-on to Rapid-Acting Insulin Secretagogues in Type 2 Diabetes
A Long-Term, Open-Label Study to Investigate the Long-Term Safety of SYR-322 When Used in Combination With Rapid-Acting Insulin Secretagogues in Subjects With Type 2 Diabetes in Japan

The purpose of this study is to evaluate the safety and efficacy of alogliptin as an add-on to a rapid-acting insulin secretagogue (medicine that stimulates insulin release) in type 2 diabetic patients with inadequate blood glucose control despite treatment with a rapid-acting insulin secretagogue as well as diet and exercise therapies.

One alogliptin 25 mg tablet was orally administered once daily before breakfast for up to 52 weeks.

The dose of alogliptin was adjusted according to the severity of the participant's renal dysfunction based on serum creatinine (SCr) levels. Participants with moderate renal dysfunction (SCr, >1.4 - ≤2.4 mg/dL for men and >1.2 - ≤ 2.0 mg/dL for women) received alogliptin 12.5 mg tablets.

Interventional
Phase 3
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Diabetes Mellitus
  • Drug: Alogliptin
    Alogliptin tablets
    Other Names:
    • SYR-322
    • Nesina®
  • Drug: Rapid-acting insulin secretagogue
    Either of the following commercially available rapid-acting insulin secretagogues as prescribed by the Investigator: (i) Nateglinide: Dose: 30 mg tablet or 90 mg tablet (ii) Mitiglinide calcium hydrate: Dose: 5 mg tablet or 10 mg tablet
Experimental: Alogliptin
Alogliptin 25 mg (or 12.5 mg for participants with moderate renal dysfunction) tablets, orally once daily and a rapid-acting insulin secretagogue as prescribed by the Investigator for up to 52 weeks.
Interventions:
  • Drug: Alogliptin
  • Drug: Rapid-acting insulin secretagogue
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
67
March 2013
March 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Diagnosed with type 2 diabetes mellitus.
  2. Had an HbA1c of ≥ 6.5% and < 10.0% at the start of the observation period (Week -2).
  3. Had been receiving specific diet and exercise (if applicable) therapies since at least 10 weeks prior to the start of the observation period (Week -2).
  4. Had been receiving basic diabetes treatment with a rapid-acting insulin secretagogue (nateglinide or mitiglinide calcium hydrate) alone using a stable dosage regimen since at least 10 weeks prior to the start of the observation period (Week -2).
  5. Was suitable for combination therapy of either of the above rapid-acting insulin secretagogues (nateglinide or mitiglinide calcium hydrate) and another antidiabetic drug at the start of the observation period (Week -2) in the investigator's or subinvestigator's opinion.
  6. Participants complicated by hypertension had stable blood pressure control and needed neither dose adjustment of the ongoing antihypertensive (including discontinuation and interruption) nor additional use of another antihypertensive throughout the duration of the study in the investigator's or subinvestigator's opinion.
  7. Male or female and aged 20 years or older at the time of signing of informed consent.
  8. If female, and of child-bearing potential and sexually active with a nonsterilized male partner agreed to use adequate contraception routinely from signing of informed consent throughout the duration of the study.
  9. Visited the study site on an outpatient basis during the observation period.
  10. Was capable of understanding and complying with protocol requirements in the investigator's or subinvestigator's opinion.
  11. Signed and dated the informed consent documents prior to the start of any study procedures.

Exclusion Criteria:

  1. Severe renal dysfunction or end-stage renal disease [e.g., a serum creatinine (SCr) level of >2.4 mg/dL (men) or >2.0 mg/dL (women) at the start of the observation period (Week -2)].
  2. Obvious clinical manifestations of hepatic impairment [e.g., an aspartate aminotransferase (AST) or alanine aminotransferase (ALT) value of ≥ 2.5 times the upper limit of normal at the start of the observation period (Week -2)].
  3. Any serious cardiac disease, serious cerebrovascular disorder, or serious pancreatic or hematological disease (e.g., requiring hospitalization for treatment).
  4. Systolic blood pressure of ≥ 180 mmHg or diastolic blood pressure of ≥ 110 mmHg during the observation period.
  5. A condition requiring insulin for blood glucose control (e.g., a patient with severe ketosis, diabetic coma or precoma, type 1 diabetes mellitus, severe infection, a pre- or post-operative condition, or serious trauma).
  6. Malignant tumor.
  7. History of hypersensitivity or allergies to dipeptidyl-peptidase-4 (DPP-4) inhibitors.
  8. A habitual drinker whose daily alcohol consumption was >100 mL on average.
  9. A history of drug abuse (defined as any illicit drug use) or alcohol abuse.
  10. Required to take excluded medications during the duration of the study.
  11. Previously received SYR-322 or Nesina® Tablets in a clinical study or as a therapeutic drug.
  12. Received any investigational product (including investigational products for postmarketing clinical studies) within 12 weeks prior to the start of the observation period.
  13. Had participated in another clinical study at signing of informed consent.
  14. If female, was pregnant or lactating, or intended to become pregnant between signing of informed consent and 1 month after the end of the study; or intended to donate ova during such time period.
  15. A study site employee, an immediate family member of a study site employee or in a dependent relationship with a study site employee who was involved in the conduct of this study (e.g., spouse, parent, child, sibling), or might consent under duress.
  16. Changed the dosing regimen of the ongoing rapid-acting insulin secretagogue during the observation period.
  17. History of hypersensitivity or allergies to rapid-acting insulin secretagogues.
  18. Any condition for which Nesina® Tablets, nateglinide, or mitiglinide calcium hydrate was contraindicated as defined in their package inserts.
  19. Otherwise ineligible for participation in the study in the investigator's or subinvestigator's opinion.
Both
20 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Japan
 
NCT01456130
SYR-322/OCT-901, U1111-1124-8848, JapicCTI-111643
Not Provided
Takeda
Takeda
Not Provided
Study Director: Medical Director, Clinical Science Takeda
Takeda
March 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP